William Blair Comments on TransMedics Group, Inc.'s Q2 2024 Earnings (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) - Stock analysts at William Blair upped their Q2 2024 EPS estimates for TransMedics Group in a research note issued on Tuesday, April 30th. William Blair analyst R. Daniels now forecasts that the company will post earnings of $0.10 per share for the quarter, up from their prior estimate of ($0.11). The consensus estimate for TransMedics Group's current full-year earnings is ($0.14) per share. William Blair also issued estimates for TransMedics Group's Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.15) EPS, FY2024 earnings at $0.23 EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.02) EPS and Q4 2025 earnings at $0.28 EPS.

Other equities analysts also recently issued reports about the company. Piper Sandler restated an "overweight" rating and set a $120.00 price objective (up from $95.00) on shares of TransMedics Group in a research report on Wednesday. JPMorgan Chase & Co. boosted their price objective on TransMedics Group from $105.00 to $127.00 and gave the company an "overweight" rating in a report on Wednesday. TD Cowen upped their target price on TransMedics Group from $100.00 to $130.00 and gave the stock a "buy" rating in a research report on Wednesday. Oppenheimer lifted their price target on shares of TransMedics Group from $105.00 to $125.00 and gave the company an "outperform" rating in a research report on Wednesday. Finally, Morgan Stanley upped their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $119.00.

TransMedics Group Trading Up 2.9 %

NASDAQ:TMDX traded up $3.55 during trading hours on Friday, hitting $127.99. 1,543,089 shares of the company were exchanged, compared to its average volume of 765,449. The company has a fifty day simple moving average of $84.64 and a 200 day simple moving average of $76.26. TransMedics Group has a one year low of $36.42 and a one year high of $129.66. The stock has a market capitalization of $4.19 billion, a price-to-earnings ratio of -366.00 and a beta of 1.87. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The firm had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. During the same period last year, the company earned ($0.08) earnings per share. The business's quarterly revenue was up 132.9% on a year-over-year basis.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 63,260 shares of the business's stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total value of $6,866,240.40. Following the transaction, the insider now directly owns 9,792 shares in the company, valued at $1,062,823.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other TransMedics Group news, CFO Stephen Gordon sold 15,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $74.01, for a total value of $1,110,150.00. Following the sale, the chief financial officer now directly owns 23,299 shares in the company, valued at approximately $1,724,358.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tamer I. Khayal sold 63,260 shares of the company's stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the completion of the transaction, the insider now directly owns 9,792 shares in the company, valued at approximately $1,062,823.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 236,378 shares of company stock worth $23,633,449. Insiders own 7.00% of the company's stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently bought and sold shares of the stock. Harbour Capital Advisors LLC increased its holdings in shares of TransMedics Group by 1.7% in the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company's stock worth $627,000 after buying an additional 140 shares during the period. RiverPark Advisors LLC grew its holdings in TransMedics Group by 19.5% in the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company's stock worth $104,000 after acquiring an additional 215 shares during the last quarter. First Horizon Advisors Inc. increased its position in shares of TransMedics Group by 26.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company's stock valued at $83,000 after acquiring an additional 222 shares during the period. Park Avenue Securities LLC raised its stake in shares of TransMedics Group by 3.4% during the first quarter. Park Avenue Securities LLC now owns 11,374 shares of the company's stock valued at $841,000 after acquiring an additional 372 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in shares of TransMedics Group during the first quarter worth about $30,000. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.